Document is current
Any future updates will be listed below
-
Authors
Quigley, Savannah E.
Quigg, Kellen H. https://orcid.org/0000-0003-4365-2298
Goutman, Stephen A. https://orcid.org/0000-0001-8780-6637
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01NS120926, R01NS127188)
Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry (R01TS000344, R01TS000327)
James and Margaret Hiller and Linda and Eric Novak
- License Information
-
More Information
Article History
Received: 18 March 2025
Accepted: 5 August 2025
First Online: 2 September 2025
Declarations
:
: This work was funded by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (R01NS120926 and R01NS127188 to S.A.G.), the Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry (R01TS000344 and R01TS000327 to S.A.G.), and James and Margaret Hiller and Linda and Eric Novak (S.A.G.).
: S.A.G. is listed as inventor on a patent, issue number US10660895, held by University of Michigan titled “Methods for Treating Amyotrophic Lateral Sclerosis” that targets immune pathways for use in ALS therapeutics. Scientific consulting for Evidera. S.E.Q. and K.H.Q. have no relevant financial or non-financial interests to disclose.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: S.A.G. conceived the idea for the article. S.E.Q. and K.H.Q. performed the literature search, and all authors drafted, reviewed, and critically revised the final manuscript.
